Supplemental material
Journal of Medical Economics
Volume 25, 2022 - Issue 1
Respiratory Medicine
Levalbuterol vs. albuterol for hospitalized patients with COPD in China: cost-utility and budget impact analysis
Lei Chena School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China
https://orcid.org/0000-0002-6573-2849
https://orcid.org/0000-0002-6573-2849, Xianqiu Chenb Department of Pulmonary and Critical Care Medicine, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, Chinahttps://orcid.org/0000-0002-1234-1027
https://orcid.org/0000-0002-1234-1027, , & Yang Hub Department of Pulmonary and Critical Care Medicine, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, ChinaCorrespondence[email protected]
https://orcid.org/0000-0002-4965-7885
https://orcid.org/0000-0002-4965-7885Related Research Data
Levalbuterol versus albuterol for hospitalized patients with COPD in China: cost-utility and budget impact analysis
Source:
Taylor & Francis
Linking provided by
